By Pete Gallo Sam Isaly’s biotech and pharma hedge fund looks to have a winner on its hands. OrbiMed Healthcare Fund Management is the largest shareholder in Amarin, a biopharmaceutical firm whose stock has produced spectacular results, thanks to a recent flurry